776 abstracts found.



Results filter

Targeting EZH2 in haematological malignancies

Year:

Session type:

Patrick Trojer1
1Constellation Pharmaceuticals, Cambridge, USA

Molecular stratification and clinical management of adult high-grade glioma: Lessons from the elderly trials

Year:

Session type:

Michael Weller1
1University Hospital Zurich, Zurich, Switzerland

The issues with tissues

Year:

Session type:

Mairead MacKenzie1
1Independent Cancer Patients' Voice, London, UK

Intra-tumour heterogeneity reflects cancer evolutionary dynamics: Implications for patient stratification

Year:

Session type:

Colin Watts1
1University of Cambridge, Cambridge, UK

The critical need for longitudinal tissue and blood sample collection in cancer research

Year:

Session type:

Mariam Jamal-Hanjani1, Matthew G Krebs2
1University College London, London, UK, 2The Paterson Institute for Cancer Research, Manchester, UK

‘Real world’ data: Opportunities and challenges

Year:

Session type:

David Ford1
1Swansea University, Swansea, UK

Challenges in using samples for clinical research: A pan-European perspective

Year:

Session type:

Jacqueline Hall1
1EORTC Formerly Head of Translational Research Unit, European Organisation for Research and Treatment of Cancer

Impact of ‘real world data’ on cancer patient outcomes and care

Year:

Session type:

Anna Gavin1
1Northern Ireland Cancer Registry, Queen's University Belfast, Belfast, UK

Consent: Asking the question?

Year:

Session type:

Hilary Stobart1
1Member of PPI Advisory Group and Volunteer, Nottingham Health Science Biobank, Nottingham University Hospitals NHS Trust, Nottingham, UK

Re-shaping clinical practice in neuroendocrine tumours (NETs)

Year:

Session type:

John Primrose1, Juan Valle2
1University of Southampton, Southampton, UK, 2The Christie NHS Foundation Trust, Manchester, UK

Application of nanotechnology to oncology

Year:

Session type:

Katherine Vallis1
1Gray Institute for Radiation Oncology & Biology, Oxford, UK

Integrated genomic analysis and application of single cell and circulating free DNA sequencing in NET management

Year:

Session type:

Chrissie Thirlwell1
1University College London Cancer Institute and Royal Free Hospital NET Unit, London, UK

Engineering of polymeric nanoparticles for medical applications

Year:

Session type:

Omid Farokhzad1
1Harvard Medical School, Boston, UK

Theranostics: From molecular imaging using PET/CT to personalised therapy of over 1100 patients with neuroendocrine tumours (NETs)

Year:

Session type:

Harshad R Kulkarni1
1ENETS Center of Excellence, Zentralklinik Bad Berka, Germany

Nanosized agents for imaging guided drug delivery

Year:

Session type:

Simonetta Geninatti Crich1
1University of Torino, Torino, Italy

Systemic therapy options for NETS: When and what

Year:

Session type:

Ramon Salazar1
1Institut Català d’Oncologia, L´Hospitalet de Llobregat, Barcelona, Spain

Autophagy, senescence and cell death

Year:

Session type:

Daniel Murphy1,2
1University of Glasgow Institute of Cancer Sciences, Glasgow, UK, 2The Beatson Institute for Cancer Research, Glasgow, UK

Smarter surgery for better cancer outcomes

Year:

Session type:

Dion Morton1
1University of Birmingham, Birmingham, UK

Smarter surgery for better cancer outcomes: Leading the way with breast cancer

Year:

Session type:

Alastair M Thompson1
1Dundee Cancer Center, Dundee, UK

Surgeons and oncologists: Optimising surgery within multimodality treatment

Year:

Session type:

David Sebag-Montefiore1, Simon Bach2
1University of Leeds, Leeds, UK, 2Queen Elizabeth Hospital, Birmingham, UK

Life-altering late effects and their management in survivors of childhood malignancy

Year:

Session type:

Rod Skinner1,2
1Great North Children’s Hospital, Newcastle, UK, 2Royal Victoria Infirmary, Newcastle, UK

Smarter trial designs in surgical oncology

Year:

Session type:

Jane Blazeby1
1University of Bristol, Bristol, UK

Frequency, timing and causes of late mortality in survivors of childhood malignancy

Year:

Session type:

Raoul Reulen1
1University of Birmingham, Birmingham, UK

Targeting the epigenome

Year:

Session type:

Robert Brown1
1Imperial College London, London, UK

ACP McElwain Prize – Antibodies of the IgE class: Preclinical evaluations for therapeutic use in the treatment of solid tumours

Year:

Session type:

Debra Josephs
King's College London and Guy's and St Thomas' Hospitals, London, UK

The development of cutaneous squamous lesions in patients treated with vemurafenib: A possible role for human papillomavirus in addition to activated RAS

Year:

Session type:

Karin Purdie1, Andrew South2, Mary Sommerlad3, Hasan Rizvi3, Irene Leigh2, Charlotte Proby2, Catherine Harwood1,3
1Centre for Cutaneous Research, Blizard Institute, Queen Mary University of London, London, UK, 2Division of Cancer Research Jacqui Wood Cancer Centre, Ninewells Hospital and Medical School, Dundee, UK, 3Department of Dermatology, Barts Health NHS Trust, London, UK

How does RAS contribute to cutaneous squamous cell carcinoma?

Year:

Session type:

Angela McHugh1, Mark Saville1, Catherine Harwood2, Karin Purdie2, Alan Evans3, Aidan Rose1, Colin Fleming4, Irene Leigh1, Andrew South1, Charlotte Proby1
1Division of Cancer Research, Ninewells Hospital & Medical School, University of Dundee, Dundee, UK, 2Centre for Cutaneous Research, Barts and the London Queen Mary University of London, London, UK, 3Department of Pathology, Ninewells Hospital & Medical School, Dundee, UK, 4Department of Dermatology, Ninewells Hospital, Dundee, UK

Changes in glutathione metabolism mediate the resistance of EGFR-T790M mutant lung cancer cells to erlotinib

Year:

Session type:

William B Stokes1, Hongde Li2, Rajat Roy1, Emily Chater1, Michael Seckl1, Yulan Wang2, Huiru Tang2, Olivier E Pardo1
1Imperial College London, London, UK, 2Chinese Academy of Sciences, Wuhan, China

Clinical outcome following video-assisted thoracoscopic surgery (VATS) or thoracotomy in the surgical management of lung cancer: A multicentre UK analysis from 2001-2013

Year:

Session type:

Jason Sangha1, Felicity Evison2, Daniel Ray2, Paul Moss2
1University of Birmingham, Birmingham, UK, 2University of Birmingham, University Hospitals Birmingham NHS Foundation Trust and Birmingham CRUK Centre, Birmingham, UK

The glycoprotein, Decorin is a novel anti-proliferative and anti-angiogenic treatment for glioblastoma multiforme

Year:

Session type:

Hannah Shereef1, Lisa Hill1,2, Kismet Hossain-Ibrahim3, Roy Bicknell4, Ann Logan1, Garth Cruickshank2
1School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK, 2Department of Neurosurgery, University Hospitals Birmingham, Birmingham, UK, 3Department of Neurosurgery, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, 4School of Immunity and Infection and Cancer Studies, University of Birmingham, Birmingham, UK

Preliminary results of the GALA-5 study: an evaluation of the tolerability and feasibility of combining 5-Amino-Levulinic Acid (5-ALA) with carmustine wafers (Gliadel) in the surgical management of primary glioblastoma

Year:

Session type:

Colin Watts1, Katharina Wanek2, Nicolas Counsell2, Paul Smith2
1University of Cambridge, Cambridge, UK, 2UCL Clinical Trials Unit, London, UK

Cancer in patients with mental illness – differences and outcomes

Year:

Session type:

Anna Gavin1, Suzanne Cromie1, David Donnelly1
1Queen's University Belfast, Belfast, UK

Simultaneous cone beam CT scanning during prostate radiotherapy produces clinically useful images

Year:

Session type:

Peter Dickinson1, Julie Stratford1, Chris Boylan1, Carl Rowbottom1, Ananya Choudhury1
1The Christie NHS Foundation Trust, Manchester, UK

The effect of repeated invitations to prevalence screening on inequalities in the NHS Bowel Cancer Screening Programme

Year:

Session type:

Siu Hing Lo1, Christian von Wagner1, Julia Snowball2, Stephen Halloran2,3, Jane Wardle1
1University College London, London, UK, 2Bowel Cancer Screening Programme, Southern Hub, Royal Surrey County Hospital, Surrey, UK, 3University of Surrey, Surrey, UK

FDG-PET parameters as predictors for outcome in non small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT)

Year:

Session type:

Mymoona Alzouebi1, Manil Subesinghe2, S Ramasamy1, Michael Snee1, Robert Turner1, Robert Stuart1, Kevin Franks1, Helene Thygesen3, Katy Clarke1
1St James's University Hospital, Leeds, UK, 2Leeds Teaching Hospital, Leeds, UK, 3University of Leeds, Leeds, UK

The c-MET-JAK1/2-STAT3 signalling axis is regulated by ADAM17 and is a key mediator of resistance to MEK inhibition in KRAS mutant colorectal cancer

Year:

Session type:

Sandra Van Schaeybroeck1, Murugan Kalimutho1, Philip Dunne1, Wendy Allen1, Puthen Jithesh1, Cathy Fenning1, Robbie Carson1, Daniel Longley1, Patrick Johnston1
1Queen's University Belfast, Belfast, UK

Does the incidental coverage of axillary nodes by either standard breast or  high tangential radiotherapy fields explain Z0011 trial results?

Year:

Session type:

Marjory Maclennan1, Sanjana Masinghe1, Barbara Cadwallader1, Josie Cameron1, Avril Middleton1, Carolyn Bedi1, Tamasin Evans1
1Edinburgh Cancer Centre, Edinburgh, UK

Measurement of the acute response to hypoxia in rat tumours in vivo using magnetic resonance spectroscopy and hyperpolarised pyruvate

Year:

Session type:

Steven Reynolds1, Joanne Bluff1, Tooba Alizadeh1, Samira Kazan1, Stephen Metcalf1, Emily Wholey1, Leigh Williams1, Adriana Bucur1, Becky Bibby1, Martyn Paley1, Gillian M Tozer1
1University of Sheffield, Sheffield, UK

A significant reduction in positive circumferential margin involvement is achieved by combining a low rectal cancer MRI staging system with clinical assessment and sound patient management:experience from the MERCURY II Low Rectal Cancer Study.

Year:

Session type:

Nick Battersby1, Peter How1, Phil Quirke3, Brendan Moran1, Gina Brown2, The Mercury II study group1
1Pelican Cancer Foundation, Basingstoke, UK, 2The Royal Marsden Hospital, London, UK, 3St James' Hospital, Leeds, UK

PTEN phosphatase-independent maintenance of apical membrane integrity during colorectal glandular morphogenesis

Year:

Session type:

Ravi Deevi1
1Queen’s University of Belfast, Belfast, UK

Increased blood flow to human rectal cancer induced by nelfinavir and radiotherapy

Year:

Session type:

Esme Hill1,2, Jamie Franklin2, Mike Partridge1, Somnath Mukherjee1,2, Jun Li1, Kwun-Ye Chu2, Mark Anderson1,2, Ricky Sharma1,2
1University of Oxford, Oxford, UK, 2Churchill Hospital, Oxford, UK

Parallel functional genetic and compound screens identify WEE1 inhibition as a therapeutic strategy for cancers with defects in Fanconi Anaemia and HR pathways

Year:

Session type:

Marieke Aarts1, Ilirjana Bajrami1, Richard Elliott1, Christopher Lord1, Alan Ashworth1, Nicholas Turner1,2
1Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK, 2Breast Unit, Royal Marsden Hospital, London, UK

An evidence-based UK IMRT solution for anal cancer: the development of the control arm for future UK led clinical trials.

Year:

Session type:

Rebecca Muirhead1, Richard A Adams2, Duncan C Gilbert3, Mark Harrison4, Robert Glynne-Jones4, David Sebag-Montefiore5, Maria A Hawkins1
1The Gray Institute for Radiation Oncology & Biology, Oxford, UK, 2School of Medicine, Cardiff University, Cardiff, UK, 3Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK, 4Mount Vernon Hospital, Northwood, UK, 5University of Leeds, St James Institute of Oncology, Leeds, UK

The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF mutant colorectal cancer cell lines

Year:

Session type:

Basak Celtikci1, Robert Carson1, Sandra Van Schaeybroeck1, Patrick Johnston1
1Queen's University, Belfast, UK

Preoperative chemoradiation (CRT) with concurrent cetuximab, irinotecan and capecitabine in MRI-defined locally advanced rectal cancer (LARC) within the phase II EXCITE trial: Relationship of epidermal growth factor receptor (EGFR) pathway mutations to histological response and survival.

Year:

Session type:

Simon Gollins1, Nick West2, Phil Quirke2, Arthur Sun Myint3, Mark Saunders4, Shabbir Susnerwala5, David Sebag-Montefiore2, Sharadah Essapen6, Les Samuel7, Bruce Sizer8, Sandy Beare9, Emma Lawrie9, Mark Jitlal9
1North Wales Cancer Treatment Centre, Denbighshire, UK, 2Leeds Teaching Hospitals NHS Trust, Leeds, UK, 3Clatterbridge Cancer Centre, Bebington, UK, 4Christie NHS Foundation Trust, Manchester, UK, 5Rosemere Cancer Centre, Preston, UK, 6St Lukes Cancer Centre, Guildford, UK, 7Aberdeen Royal Infirmary, Aberdeen, UK, 8Essex County Hospital, Colchester, UK, 9Cancer Research UK & UCL Cancer Trials Centre, London, UK

Replication stress links structural and numerical cancer chromosomal instability

Year:

Session type:

Rebecca Burrell1, Sarah McClelland1,9, David Endesfelder1,2, Petra Groth3, Marie-Christine Weller3, Nadeem Shaikh1, Enric Domingo4, Nnennaya Kanu1,5, Sally Dewhurst1, Eva Groonroos1, Su Kit Chew1,5, Andrew Rowan1, Arne Schenk2, Michal Scheffer6, Michael Howell1, Maik Kschischo2, Axel Behrens1, Thomas Helleday3, Jiri Bartek7,8, Ian Tomlinson4
1CRUK, London, UK, 2University of Applied Sciences, Koblenz, Germany, 3Karolinska Insitutet, Stockholm, Sweden, 4The Wellcome trust Centre for Human Genetics, Oxford, UK, 5UCL Cancer Institute, London, UK, 6Weizmann Institute of Science, Rehovot, Israel, 7Danish Cancer Society Research Centre, Copenhagen, Denmark, 8Institute of Molecular and Translational Medicine, Olomouc, Czech Republic, 9Barts Cancer Institute, London, UK

Signalling pathways required for Normal Fibroblast (NF) to Cancer-Associated Fibroblast (CAF) conversion

Year:

Session type:

Nil EGE1, Fernando Calvo1, Erik Sahai1
1Cancer Resarch UK, London, UK

Tetraploidy is permissive for chromosomal instability and accelerates cancer genome evolution

Year:

Session type:

Sally Dewhurst1, Nicholas McGranahan1, Rebecca Burrell1, Andrew Rowan1, Eva Gronroos1, Charles Swanton1,2
1Cancer Research UK, London Research Institute, London, UK, 2University College London Cancer Institute, Huntley Street, London, UK

Clinical implications of a prostate cancer risk SNP profile in 2 treatment cohorts

Year:

Session type:

Chee Goh1, Edward Saunders1, Daniel Leongamornlert1, Tokhir Dadaev1, Malgorzata Tymrakiewicz1, Karen Thomas2, Elizabeth Selvadurai2, Ruth Woode-Amissah2, Nadiya Mahmud1, Elena Castro3, David Olmos3, Michelle Guy1, Koveela Govindasami1, Rosemary Wilkinson1, Emma Sawyer1, Ali Amin Al Olama4, Douglas Easton4, Zsofia Kote-Jarai1, Chris Parker1,2, Rosalind Eeles1,2
1The Institute of Cancer Research, London, UK, 2The Royal Marsden NHS Foundation Trust, London, UK, (CNIO) Spanish National Cancer Research Centre, 4The University of Cambridge, Cambridge, UK

Lineage tracing reveals the cellular basis of early metastasis in oesophageal squamous carcinoma

Year:

Session type:

Julia Frede1, Philip Greulich2, Benjamin Simons2, Maria Alcolea1, Philip Jones1
1MRC Cancer Cell Unit, Cambridge, UK, 2University of Cambridge, Cambridge, UK